Mod GRF (1-29) & GHRP-2 Blend (10mg)

This 10mg blend combines Mod GRF (1-29) 5mg and GHRP-2 5mg in a single vial, synthesized and lyophilized in the USA.

Each vial of Mod GRF (1-29) & GHRP-2 Blend (10mg) contains a pre-weighed ratio of Mod GRF (1-29) 5mg, GHRP-2 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.

Investigations of Mod GRF (1-29) & GHRP-2 Blend (10mg) commonly measure secretagogue activity and downstream signaling markers in controlled cell models.

Researchers pair Mod GRF (1-29) & GHRP-2 Blend (10mg) with pulse-profile analysis to characterize its release dynamics under standardized conditions.

Comparative studies of Mod GRF (1-29) & GHRP-2 Blend (10mg) often benchmark its potency against reference peptides in the same family.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Mod GRF (1-29) & GHRP-2 Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults^[1] — This clinical study evaluated how a single injection of CJC-1295, a long-acting analog of growth hormone-releasing hormone, affects GH and IGF-I secretion in healthy adults. The authors examined the duration and magnitude of the hormonal response to the modified GHRH peptide. The results suggested that CJC-1295 can produce sustained elevations of GH and IGF-I, supporting its characterization as a long-acting GHRH analog. (The Journal of Clinical Endocrinology & Metabolism 2006)

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog^[2] — This study investigated whether continuous stimulation with the long-acting GHRH analog CJC-1295 preserves the natural pulsatile pattern of growth hormone secretion. Healthy men were studied during ongoing exposure to the peptide to assess both trough and peak GH dynamics. The findings indicated that GH pulsatility persists even under continuous GHRH analog stimulation, while baseline levels were elevated. (The Journal of Clinical Endocrinology & Metabolism 2006)

Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women^[3] — This study examined the effects of a 30-day continuous subcutaneous infusion of GH-releasing peptide-2 (GHRP-2) on the growth hormone axis in older men and women. The authors measured pulsatile GH secretion as well as IGF-I, IGFBP-3, and IGFBP-5 concentrations throughout the infusion period. The results suggested that prolonged GHRP-2 administration sustains elevations of GH and related IGF markers in older adults. (The Journal of Clinical Endocrinology & Metabolism 2004)

Development of growth hormone secretagogues^[4] — This review traced the discovery and development of growth hormone secretagogues, including the synthetic peptides that act on the ghrelin receptor pathway. The author summarized how these compounds were identified and characterized as stimulators of GH release. The review provided a conceptual framework for understanding GHRP-class peptides such as GHRP-2 and their mechanism of action. (Endocrine Reviews 2005)

References

1. Teichman SL, et al.. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/3/799/10779632/jcem0799.p…
2. Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog." The Journal of Clinical Endocrinology & Metabolism. 2006. academic.oup.com/jcem/article-pdf/91/12/4792/9059878/jcem4792.…
3. Bowers CY, et al.. "Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and Women." The Journal of Clinical Endocrinology & Metabolism. 2004. academic.oup.com/jcem/article-pdf/89/5/2290/10743682/jcem2290.…
4. Smith RG. "Development of growth hormone secretagogues." Endocrine Reviews. 2005. pubmed.ncbi.nlm.nih.gov/15814848/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.